Advertisement

Related Videos

Welcome and Introduction to Vi3C

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
18
Today In Oncology
Verifying the Seen and Unseen by AI in Cancer Imaging
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo